Core Lead
Dr. Schneider is internationally recognized in clinical drug development for Alzheimer’s disease, cognitive disorders, and neuropsychiatric and behavioral disorders. He has led numerous clinical trials of therapeutics for Alzheimer’s disease and mild cognitive impairment, consults with many development programs, and has helped design and run several early- and later-phase proprietary development programs for Alzheimer’s disease. He has directed multicenter trials in Alzheimer’s disease and major depression, including the paradigm-shifting CATIE-AD trial. More recently, he has examined evidence for changes over time in Alzheimer’s trial characteristics and outcomes, and he uses trial simulations from large meta-databases to assess how Alzheimer’s-related biomarkers and genotypes affect the efficiency of targeted clinical trials. He serves on the steering committees of the NIH ADCS, the NIH ADNI, and the Banner Alzheimer’s Prevention Initiative.
CHP-216, 1540 Alcazar Street, Health Sciences Campus, Los Angeles, CA 90089-9009